search icon

    Market Snapshot

    • S&P Futures

      3,914.75

    • Dow Futures

      31,478

    • Nasdaq Futures

      12,132.75

    blog search icon

    Akebia Therapeutics, Inc.

    (NASDAQ:AKBA)

    $0.39

    $0.03

    10.51%

    Akebia Therapeutics, Inc. Chart

    AKBA Stock Price Today

    Akebia Therapeutics, Inc. (AKBA) stock rallied over 10.51% intraday to trade at $0.39 a share on NASDAQ. The stock opened with a gain of 16.42% at $0.355 and touched an intraday high of $0.396, rising 9.55% against the last close of $0.356. The stock went to a low of $0.351 during the session.

    Stock Snapshot

    $0.356

    Prev. Close

    67.72 Million

    Market Cap

    $0.351

    Day Low

    $0.355

    Open

    179.6 Million

    Number of Shares

    $0.396

    Day High

    -

    P/E ratio

    -1.61

    EPS (TTM)

    0.83

    Cash Flow per Share

    9.92

    Free Float in %

    0.79

    Book Value

    7,815,940

    Volume

    Akebia Therapeutics, Inc. Historical Data

    DateOpenHighLowCloseVolume
    2022-06-23$0.355$0.396$0.351$0.3937,831,600
    2022-06-22$0.335$0.375$0.33$0.3567,101,100
    2022-06-21$0.345$0.356$0.323$0.3459,179,100
    2022-06-17$0.319$0.36$0.312$0.34221,181,600
    2022-06-16$0.341$0.347$0.3$0.32118,279,700
    2022-06-15$0.39$0.404$0.335$0.35324,566,000
    2022-06-14$0.379$0.379$0.335$0.3544,009,200
    2022-06-13$0.39$0.395$0.361$0.3676,035,600
    2022-06-10$0.421$0.43$0.393$0.4086,104,500
    2022-06-09$0.445$0.459$0.421$0.4425,356,800

    Contact Details

    245 First Street
    Suite 1400
    Cambridge, MA 02142
    United States

    Webiste:AKBA

    617 871 2098

    Company Information

    Employees-

    Beta1.48

    Sales or Revenue213.58 Million

    5Y Sales Change168.30%

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

    Frequently Asked Questions

    icon

    What is the current Akebia Therapeutics, Inc. (AKBA) stock price?

    Akebia Therapeutics, Inc. (NASDAQ: AKBA) stock price is $0.39 as of the last check on Thursday, June 23. During the trading session, AKBA stock reached the peak price of $0.396 while $0.351 was the lowest point it dropped to.

    icon

    AKBA's industry and sector of operation?

    The NASDAQ listed AKBA is part of Biotechnology industry that operates in the broader Health Care sector. Akebia Therapeutics, Inc. , a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.

    icon

    Who are the executives of AKBA?

    Mr. Jason A. Amello
    Exec. Officer
    Mr. John P. Butler MBA
    CEO, Pres & Director
    Mr. David A. Spellman
    Sr. VP, CFO & Treasurer
    Mr. Michel Dahan
    Sr. VP & COO

    icon

    What is the AKBA stock price today?

    AKBA stock traded closed the last session at $0.393, which is $0.03 or 10.51% lower than its previous close of $0.356. AKBA's current trading price is 31.07% lower than its 52-week high of $4.33 where as its distance from 52-week low of 0.30% is -90.92%.

    icon

    How many employees does AKBA have?

    Number of AKBA employees currently stands at -. AKBA operates from 245 First Street, Suite 1400, Cambridge, MA 02142, United States.

    icon

    Link for AKBA official website?

    Official Webiste of $AKBA is: https://www.akebia.com

    icon

    How do I contact AKBA?

    AKBA could be contacted at AKBA operates from 245 First Street, Suite 1400, Cambridge, MA 02142, United States, or at phone #617 871 2098 and can also be accessed through its website.

    icon

    How many shares of AKBA are traded daily?

    AKBA stock volume for the day was 7,815,940 shares while in the previous session number of AKBA shares traded was 7,831,600 . The average number of AKBA shares traded daily for last 3 months was 12.48 Million.

    icon

    How much did AKBA change today?

    The percentage change in AKBA stock occurred in the recent session was 10.51% while the dollar amount for the price change in AKBA stock was $0.03.

    icon

    What price range AKBA stock been trading in?

    In the recent session, the day high for AKBA stock was $0.396 while the low for AKBA stock touched on the day was $0.351.

    icon

    What is the market cap of AKBA currently?

    The market value of AKBA currently stands at 67.72 Million with its latest stock price at $0.39 and 179.6 Million of its shares outstanding.